Respiratory Distress Syndrome — Neonatal

Neonatal respiratory distress syndrome (RDS), formerly called hyaline membrane disease, is an acute respiratory disease affecting primarily premature infants characterized by severe hypoxemia, hypercapnia, and respiratory failure within hours of birth. It is the leading cause of morbidity and mortality in preterm neonates, with incidence inversely related to gestational age—affecting approximately 60% of infants <28 weeks gestation but <5% of those >35 weeks. The pathophysiology centers on deficiency of pulmonary surfactant, a lipid-protein complex essential for reducing alveolar surface tension. RDS remains clinically critical because early recognition and appropriate management with exogenous surfactant replacement and respiratory support dramatically alter outcomes; survival rates have improved from <10% in the 1960s to >90% in modern neonatal intensive care units. Understanding the molecular basis, clinical trajectory, and therapeutic interventions is essential for USMLE Step 2 CK as RDS represents a paradigm of neonatal critical illness and the intersection of respiratory physiology, pharmacology, and developmental biology.

The fundamental defect in RDS involves inadequate production and secretion of pulmonary surfactant, a complex mixture of lipids (90% by weight) and proteins (10% by weight) that is essential for neonatal respiratory function.

Surfactant is produced by type II pneumocytes beginning at approximately 24-28 weeks gestation, with production accelerating significantly after 35 weeks. The major lipid component is dipalmitoylphosphatidylcholine (DPPC), which constitutes ~50% of surfactant mass and is responsible for the majority of surface tension-reducing activity. At the air-liquid interface of alveoli, surfactant molecules orient with their hydrophobic tails toward the air phase and hydrophilic heads toward the liquid, dramatically reducing surface tension according to the Laplace equation (P = 2T/r, where P is transmural pressure, T is surface tension, and r is radius). In surfactant deficiency, surface tension remains elevated; consequently, alveoli require much higher transpulmonary pressures to inflate and become markedly prone to collapse during expiration. This leads to cyclical atelectasis—repetitive opening and closing of alveoli—which causes mechanical shear stress to the fragile alveolar epithelium and generates further inflammation. The result is severe ventilation-perfusion (V/Q) mismatch with regions of profound hypoxemia and increased work of breathing.

The mechanical trauma from cyclical atelectasis and the hypoxia-reoxygenation injury trigger a cascade of inflammatory mediators. Damaged type I pneumocytes (which cover ~95% of alveolar surface area and are highly vulnerable to mechanical and oxidative stress) release cytokines including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-8 (IL-8). These cytokines recruit neutrophils into the alveolar space; neutrophil-derived proteases and reactive oxygen species cause further epithelial damage. Additionally, protein-rich edema fluid leaks from damaged capillaries into alveoli, coating the remaining surfactant and inactivating it—further exacerbating the functional surfactant deficit. Fibrin deposition in damaged alveoli creates the characteristic hyaline membranes (homogeneous, proteinaceous material lining alveolar walls) that give the disease its historical name.

The combination of collapsed alveoli and diminished surfactant activity dramatically increases the elastic work of breathing. The compliance of the lungs (change in volume per unit change in pressure) is markedly reduced. To generate adequate ventilation, infants must develop much higher transpulmonary pressures, placing enormous metabolic demands on respiratory muscles that are inherently immature and fatigue-prone (neonatal muscles have higher type II fast-twitch glycolytic fibers with limited endurance). The increased metabolic demand, combined with hypoxemia and metabolic acidosis from anaerobic metabolism, leads to progressive respiratory muscle fatigue and ventilatory failure. Infants typically progress from compensated tachypnea (respiratory rate >60 breaths/min) to grunting (forced expiration against a partially closed glottis—an attempt to generate positive end-expiratory pressure [PEEP] and maintain alveolar patency) to exhaustion and apnea.

Severe hypoxemia results from extensive V/Q mismatch (atelectatic regions receive blood flow without ventilation—true shunting). Paradoxically, hypercarbia initially may not be prominent due to compensatory hyperventilation, but as respiratory failure progresses, CO₂ retention occurs. Severe hypoxemia triggers pulmonary vasoconstriction (the pulmonary vascular bed uniquely constricts in response to hypoxia, opposite to systemic vascular response), increasing pulmonary vascular resistance and potentially causing pulmonary hypertension. If severe enough, this can lead to right-to-left shunting across fetal channels (foramen ovale and ductus arteriosus) that may remain patent in preterm infants, further worsening hypoxemia. Severe hypoxemia and acidosis also impair cardiac contractility and systemic perfusion.

Prematurity itself confers multiple compounding problems beyond simple surfactant deficiency. The preterm lung has fewer total alveoli (alveolar development continues into the early postnatal period in term infants and beyond), reduced surface area for gas exchange, and immature antioxidant systems that cannot adequately defend against oxidative stress. Metabolic acidosis from tissue hypoxia and anaerobic metabolism further depresses respiratory effort and can cause pulmonary vasoconstriction.

Prematurity is the dominant risk factor because surfactant production is gestation-dependent. The risk is inverse to gestational age: infants born at 24-28 weeks have ~60-80% risk of RDS; those at 30-34 weeks have ~25-40% risk; and those at 35-36 weeks have ~10-15% risk. Infants born at term (≥39 weeks) have minimal RDS risk unless other complications are present.

Maternal hyperglycemia causes fetal hyperinsulinemia, which inhibits type II pneumocyte maturation and delays surfactant production. This increases RDS risk even in infants delivered near term. Infants of diabetic mothers have surfactant deficiency disproportionate to their gestational age, occasionally developing RDS at 38-39 weeks.

Paradoxically, maternal hypertensive disorders appear protective, possibly through stress-induced catecholamine release that accelerates fetal lung maturation. This is not a rationale for inducing hypertension but rather an observed association.

Labor itself appears to enhance fetal lung maturation through stress hormones and release of prostaglandins. Infants delivered via planned cesarean section (without spontaneous or induced labor) have higher RDS risk compared to vaginal delivery or cesarean delivery after labor.

Male infants have higher RDS incidence and severity compared to female infants at equivalent gestational ages—this is thought to reflect sex-dependent differences in pulmonary maturation rates, with males maturing more slowly.

Being a second or higher twin has increased RDS risk, particularly if delivered at lower birth weight.

Severe perinatal hypoxia-ischemia can damage type II pneumocytes and impair surfactant function. Early-onset neonatal sepsis (particularly group B streptococcal infection) can present with RDS-like respiratory failure and should always be considered in the differential diagnosis.

Maternal chorioamnionitis, placental insufficiency, and preterm premature rupture of membranes (pPROM) increase RDS risk but may also be associated with accelerated fetal lung maturation in some cases.

Affected neonates typically present with progressive respiratory rate >60 breaths/min, often exceeding 100 breaths/min in severe cases. This represents a compensatory response to hypoxemia and the increased elastic work of breathing from low lung compliance. Parents or delivery room personnel typically notice rapid, labored breathing immediately or within minutes of birth.

Infants display obvious signs of increased respiratory effort including:

Infants may display central cyanosis (bluish discoloration of lips and tongue) reflecting significant hypoxemia with oxygen saturation typically <90-92% in room air. Peripheral cyanosis of the extremities may also be present.

Respiratory distress is often incompatible with safe oral feeding; infants may refuse the bottle or breast. Tachypneic infants cannot coordinate suck-swallow-breathe sequences and are at risk for aspiration.

The lungs typically have diminished air entry bilaterally with a characteristic "ground glass" or "salt-and-pepper" appearance on auscultation—breath sounds are quiet or absent reflecting poor ventilation of atelectatic regions. Fine inspiratory crackles (rales) may be heard in some cases. Importantly, the absence of wheezes or significant focal findings helps differentiate RDS from other causes of neonatal respiratory distress such as meconium aspiration or pneumothorax.

Severely affected infants may be limp, hypotonic, and lethargic reflecting hypoxemia and hypercarbia. Skin may appear pale or grayish. In very severe cases, infants become flaccid and apneic ("RDS look" or appearance of septic shock). Peripheral pulses may be weak or thready indicating compromised cardiac output from hypoxemia and acidosis.

The cardiac examination may reveal a hyperdynamic precordium with increased intensity of heart sounds (compensatory increase in cardiac output to maintain tissue oxygen delivery) or, in severe cases, muffled heart sounds suggesting pericardial effusion.

TTN presents similarly to RDS with tachypnea and mild-moderate respiratory distress but typically occurs after term or near-term delivery (≥35-36 weeks) and is caused by delayed clearance of fetal lung fluid rather than surfactant deficiency. TTN is usually self-limited over hours to days and responds well to supportive care; RDS in premature infants is progressive without intervention.

Preterm infants may present with tachypnea and mild respiratory distress from fluid retention even without surfactant deficiency, making early clinical differentiation challenging.

The diagnosis is strongly suggested by the clinical constellation of:

Chest radiography is the primary diagnostic imaging study and reveals characteristic findings:

The chest X-ray findings in severe RDS can be dramatic and led to the historical term "hyaline membrane disease." However, chest X-ray findings lag behind clinical presentation by several hours; very early in the disease (first 30-60 minutes), the X-ray may appear relatively normal despite severe clinical respiratory distress.

ABG reveals the pathophysiology:

SpO₂ is typically <90-92% in room air for moderate-severe RDS and may be <80-85% without supplemental oxygen. The response to supplemental oxygen helps differentiate RDS (which typically improves with supplemental O₂) from cyanotic heart disease (minimal improvement with supplemental oxygen). The hyperoxia test (comparing PaO₂ on room air vs. 100% FiO₂; PaO₂ >250 mmHg on 100% O₂ suggests cardiac disease, PaO₂ <250 mmHg suggests pulmonary/parenchymal disease) is occasionally used.

Lecithin:sphingomyelin (L:S) ratio from amniotic fluid (obtained via amniocentesis) was historically used to assess fetal lung maturity in obstetric practice (ratio >2.0 suggests maturity) and can predict RDS risk. A ratio <1.5 predicts high RDS risk. However, this test is less commonly used in modern practice given routine maternal corticosteroid use. Fetal fibronectin and phosphatidylglycerol presence in amniotic fluid are additional maturity markers.

These tests help exclude neonatal sepsis (which can present identically to RDS). WBC >15,000/μL or <5,000/μL, immature-to-total (I:T) neutrophil ratio >0.2, low platelet count, and positive blood culture suggest infection. C-reactive protein (CRP) may be elevated but is nonspecific.

This bedside scoring system quantifies respiratory distress severity:

Total score: 0 = no distress; 1-4 = mild; 5-7 = moderate; 8-10